reference/4626926

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/4626926

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Randomized Controlled Trial
endingPage	557
issn	0167-6806 1573-7217
issueIdentifier	3
pageRange	547-557
publicationName	Breast Cancer Research and Treatment
startingPage	547
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_6ae6b06b256ca9b715f72b8f817497b4
bibliographicCitation	O’Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS. A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Research and Treatment. 2018 Apr 19;170(3):547–57. doi: 10.1007/s10549-018-4770-6.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e377f85dcbca53c3a56740d6402ea5c0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_51f6503f799f8d0d5e7f67a90c96f5f1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_741734cd7dc29bb1028a5f74caeee1c9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a4699063f426427b726b348e01556f61 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89c9ae14c91a0dbfb45163393c4a7912 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_12d9fa89274d888a0e875ac47f4c6b13 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8255c82803d01a36e5cd61bd6323688d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_df52e6743fbcf4655c0d7b59e3794bdf http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-6764-2807 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7425b7130d56f5edb3d00431791934b6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c733caacafd6f76bfb1519054b755fb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_99f3dc3ad9cb10c853484a288745dd8b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0ea9c5fe815ff282b9361674a12c0268
date	2018-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1007/s10549-018-4770-6 https://pubmed.ncbi.nlm.nih.gov/29675680
isPartOf	https://portal.issn.org/resource/ISSN/0167-6806 https://portal.issn.org/resource/ISSN/1573-7217 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1254
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/ https://scigraph.springernature.com/
title	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation
discusses	http://id.nlm.nih.gov/mesh/M0028191 http://id.nlm.nih.gov/mesh/M0549299 http://id.nlm.nih.gov/mesh/M0018260 http://id.nlm.nih.gov/mesh/M0028048 http://id.nlm.nih.gov/mesh/M0287377 http://id.nlm.nih.gov/mesh/M0018226 http://id.nlm.nih.gov/mesh/M0014878 http://id.nlm.nih.gov/mesh/M0003122
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11386 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11431 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25126798 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_335366b86eab13ea9f6925279dca28aa http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8173 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_a7939d043567ee90a9f1febb314e563d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e8ad08f759b2798c1b5dca78861cc6ce http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_54e32599939667ce8030f6c1725ceac0 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60953

Total number of triples: 55.